Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety

#1756

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.

Aim(s): Aim of this study is to evaluate efficacy and safety of PPI and SSA in MEN1 related ZES.

Materials and methods: Eighteen pts with MEN1 related ZES were retrospectively evaluated (12 m, 6 f, mean age 36 yrs) for a median follow-up of 104 months (range 6-203). Gastrinoma was located in pancreas(7), pancreas and duodenum(7), duodenum(4). All pts were treated with PPI only for at least 6 months (median 12, range 6-19), afterwards SSA were added.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: somatostatin analogs, MEN1, Zollinger-Ellison syndrome,

To read the full abstract, please log into your ENETS Member account.